Concepedia

Sreeneeranj Kasichayanula

SK

Statistics

Publications

30

Citations

2.1K

H-Index

23

Active since

2004

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Bristol-Myers Squibb (Sweden)

University of Manitoba

AbbVie (United States)

Sreeneeranj Kasichayanula is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, medicine, and pharmacotherapy.

Top concepts

PharmacologyMedicinePharmacotherapyPharmacokineticsToxicologyBiochemistryDrug AnalysisPublic HealthAtherosclerosisClinical Pharmacology

Publications per year

2004–2021

30

Publications

30

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

Ralph A. DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula et al. · Diabetes Care · 2013 · 281 citations · Full text

Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Robert R. Henry, Julio Rosenstock, Steven V. Edelman et al. · Diabetes Care · 2014 · 237 citations

In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans

Mary T. Obermeier, Ming Yao, Ashish Khanna et al. · Drug Metabolism and Disposition · 2009 · 176 citations

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

L. Zhang, Yingqing Feng, James F. List et al. · Diabetes Obesity and Metabolism · 2010 · 169 citations · Full text

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

Sreeneeranj Kasichayanula, Xiaoni Liu, Melanie Pe Benito et al. · British Journal of Clinical Pharmacology · 2012 · 117 citations · Full text

1–5 of 30